JP Morgan Maintains Overweight on Avidity Biosciences, Raises Price Target to $59

Benzinga · 06/10 12:40
JP Morgan analyst Gena Wang maintains Avidity Biosciences (NASDAQ:RNA) with a Overweight and raises the price target from $57 to $59.